Underactive Bladder Therapeutics Market Size in the 7MM is Expected to Grow Major Growth by 2034, estimates DelveInsight

DelveInsight's "Underactive Bladder Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Underactive Bladder, historical and forecasted epidemiology as well as the Underactive Bladder market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

Explore In-depth insights into the evolving Underactive Bladder Market. Download sample report @ https://www.delveinsight.com/sample-request/underactive-bladder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Underactive Bladder Market Report
• In 2023, the prevalent cases of LUTS - moderate to severe in Japan were found to be 14 million and diagnosed prevalent Underactive Bladder cases were estimated to be around 0.18 million. These diagnose Underactive Bladder cases are anticipated to decrease during the forecast period (2024-2034).
• According to urodynamic findings, Underactive Bladder can be categorized into three main subtypes: Detrusor Underactivity (DU), Detrusor Hyperactivity with Impaired Contractility (DHIC), and Acontractile Detrusor (AcD). Based on evaluations conducted by DelveInsight analysts, the diagnosed prevalence of DU surpasses that of the other types of Underactive Bladder mentioned.
• According to our analysis, the prevalence of Underactive Bladder is higher among males compared to females
• DelveInsight's forecasting report of Underactive Bladder includes the Epidemiology analysis and forecast of the US, EU4 and the UK, and Japan. As per our analysis, the US had the highest diagnosed prevalent cases of Underactive Bladder in 2023, which are expected to rise, at a decent CAGR during the forecasted period (2024-2034).
• In 2023, among EU4 (Germany, France, Italy, and Spain) and the United Kingdom, Germany accounted for the highest number of diagnosed prevalent cases of Underactive Bladder i.e. around 0.2 million cases which is expected to increase by 2034.
• Based on etiologic mechanisms, the major etiologies linked to Underactive Bladder are categorized as Idiopathic, Neurogenic, Myogenic, and Others. The most common type of Underactive Bladder are due to Neurogenic causes as compared to the other etiologies.
• The leading Underactive Bladder Companies such as Taiho Pharmaceutical, Mirae Cell Bio, Astellas Pharma Europe B.V, Taiho Pharmaceutical, and others
• Promising Underactive Bladder Therapies such as TAC-302, MR-MC-01, ASP8302, TAC-302, and others

Explore Underactive Bladder Treatment algorithm and patient journeys across geographies. Get your free sample report here @ https://www.delveinsight.com/sample-request/underactive-bladder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Underactive Bladder Epidemiology Segmentation in the 7MM
• Prevalent cases of Lower urinary tract symptoms (LUTS) - moderate to severe
• Diagnosed Prevalent cases
• Gender-specific Diagnosed Prevalent cases
• Classification-specific Diagnosed Prevalent cases
• Etiology-specific Diagnosed Prevalent cases

Download the report to understand which factors are driving Underactive Bladder Epidemiology trends @ https://www.delveinsight.com/sample-request/underactive-bladder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Underactive Bladder Market Outlook
Preventing upper tract injury, avoiding bladder over distension, and minimizing residual urine are the primary objectives of effective management for Underactive Bladder. Traditional conservative treatment options, such as scheduled voiding, double voiding, alpha-blockers, and intermittent self-catheterization, aim to alleviate symptoms rather than cure the condition. However, many patients find intermittent self-catheterization challenging and require extensive training, support, and follow-up care. Despite the limitations in Underactive Bladder management and the absence of validated, effective drugs, some treatments like alpha-1 adrenoceptor antagonists, including urapidil, indoramin, and doxazosin, have been utilized to relax the urethra and reduce resistance to urine flow, particularly in women. Additionally, botulinum toxin injections may be considered to relax the external sphincter in cases of functional bladder outlet obstruction resulting in detrusor underactivity (DU).

Underactive Bladder Therapies and Companies
• TAC-302: TaihoPharmaceutical
• MR-MC-01: Mirae Cell Bio
• ASP8302: Astellas Pharma Europe B.V
• TAC-302: Taiho Pharmaceutical

Underactive Bladder Emerging Drugs
• TAC-302: Taiho Pharmaceutical
Taiho Pharmaceutical investigational molecule TAC-302 is an orally bioavailable drug, which stimulates neurite outgrowth activity in cultured peripheral neurons and has beneficial effects on bladder denervation and storage/voiding dysfunctions which is primarily considered to be effective for Detrusor underactivity with Overactive bladder. The emerging drug has completed its phase II trial in small cohort of Japanese patients but next phase has not started as yet. This may impact its launch.

Get In-Depth Knowledge on Underactive Bladder Market Trends and Forecasts with DelveInsight @ https://www.delveinsight.com/sample-request/underactive-bladder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Underactive Bladder Market Strengths
• The existing treatment paradigm consists mainly of off-label drugs. The untapped market for branded drugs presents lucrative avenues for market growth

Underactive Bladder Market Opportunities
• There is room for branded therapeutic modalities with good safety and efficacy data along with progressive clinical trials

Underactive Bladder Companies
Taiho Pharmaceutical, Mirae Cell Bio, Astellas Pharma Europe B.V, Taiho Pharmaceutical, and others

Underactive Bladder Treatment Landscape
Currently, there is no established or standardized treatment protocol for Underactive Bladder (UAB) that reliably improves patients' quality of life (QoL) while effectively preventing complications. Existing treatment approaches primarily aim to ensure adequate bladder emptying, regardless of the underlying etiology. The main goal is to promote patient engagement and adherence to prescribed therapies to reduce the likelihood of upper urinary tract damage. At this stage, patients face an increased risk of recurrent urinary tract infections (UTIs), bladder stone formation, overflow incontinence, urinary retention, impaired renal function, and chronic Valsalva voiding.

Underactive Bladder Drugs Uptake
This section focuses on the rate of uptake of the potential drugs/devices expected to be launched in the market during the study period. The analysis covers Peripheral Nerve Injuries market uptake by drugs/devices; patient uptake by therapies; and sales of each product.

Get In-Depth Knowledge on Underactive Bladder Market Trends and Forecasts with DelveInsight @ https://www.delveinsight.com/sample-request/underactive-bladder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Underactive Bladder Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Underactive Bladder Companies- Taiho Pharmaceutical, Mirae Cell Bio, Astellas Pharma Europe B.V, Taiho Pharmaceutical, and others
• Underactive Bladder Therapies- TAC-302, MR-MC-01, ASP8302, TAC-302, and others
• Underactive Bladder Therapeutic Assessment: Underactive Bladder Current marketed and Underactive Bladder emerging therapies
• Underactive Bladder Market Dynamics: Underactive Bladder market drivers and Underactive Bladder market barriers
• Underactive Bladder Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Underactive Bladder Unmet Needs, KOL's views, Analyst's views, Underactive Bladder Market Access and Reimbursement

Unlock Strategic Insights with DelveInsight's Comprehensive Underactive Bladder Market Report @ https://www.delveinsight.com/sample-request/underactive-bladder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1 Key Insights
2 Report Introduction
3 Underactive Bladder Market Overview at a Glance
4 Underactive Bladder Epidemiology and Market Methodology
5 Executive Summary of Underactive Bladder
6 Key Events
7 Disease Background and Overview: Underactive Bladder
8 Underactive Bladder Epidemiology and Patient Population
9 Underactive Bladder Patient Journey
10 Underactive Bladder Emerging Drugs: Key Cross
To be continued in the report......
11 Underactive Bladder: Major Market Analysis
12 Key Opinion Leaders' Views
13 SWOT Analysis
14 Unmet Needs
15 Reimbursement and Market Access
16 Appendix
17 DelveInsight Capabilities
18 Disclaimer

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: +91-9650213330
Address: 304 S. Jones Blvd #2432
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.